Wolverine Trading
CRVS icon

Wolverine Trading’s Corvus Pharmaceuticals CRVS Stock Holding History

Wolverine Trading’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,500
Closed -$40.8K – 5703
2025
Q2 		$40.8K Sell
10,500
-2,800
-21% -$10.2K ﹤0.01% 4388
2025
Q1 		$45K Buy
+13,300
New +$62.6K ﹤0.01% 4447
2024
Q4 		– Sell
-14,100
Closed -$72.6K – 5351
2024
Q3 		$72.6K Buy
+14,100
New +$50.6K ﹤0.01% 4441
2023
Q3 		– Sell
-15,400
Closed -$34.3K – 4584
2023
Q2 		$34.3K Buy
+15,400
New +$32K ﹤0.01% 4030
2022
Q2 		– Sell
-14,200
Closed -$22K – 4672
2022
Q1 		$22K Buy
+14,200
New +$26K ﹤0.01% 5235
2021
Q4 		– Sell
-31,000
Closed -$196K – 6032
2021
Q3 		$196K Buy
+31,000
New +$91.8K ﹤0.01% 5369

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Wolverine Trading's CRVS Position: Q4 2022 in Review

Wolverine Trading sold out of Corvus Pharmaceuticals (CRVS) in Q4 2022, closing a stake of 10,688 shares — an estimated $8K sold.

Wolverine Trading first reported a position in CRVS in Q3 2022 and held it in 1 quarter. The position peaked at $8K in Q3 2022. 41 funds tracked by Wall St. Rank hold CRVS as of Q4 2022.

  • Wolverine Trading reported no remaining Corvus Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Wolverine Trading sold 10,688 Corvus Pharmaceuticals shares in Q4 2022, an estimated $8K.
  • Wolverine Trading first reported a position in Corvus Pharmaceuticals in Q3 2022 and held it in 1 quarter.
  • Wolverine Trading's Corvus Pharmaceuticals position peaked at $8K in Q3 2022.
  • 41 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q4 2022.

Based on Wolverine Trading's 13F filing for Q4 2022, filed 14 Feb 2023.